2829263-20-7
2829263-20-7
Chemical Structure
FPR2 agonist 2
- CAS No.: 2829263-20-7
- Formula:C25H20F2N4O2
- Molecular Weight:446.45
IUPAC Name: isopropyl 3,3-difluoro-1-(hydroxymethyl)cyclobutane-1-carboxylate
InChIKey: KCNMTQVKKFREAN-QFIPXVFZSA-N
SMILES: FC1=CC=C(C=C1)NC(N[C@H](C(N2CCC3=C2C=CC(F)=C3)=O)CC4=CC=C(C=C4)C#N)=O
Biological Activity: FPR2 agonist 2 is a potent and CNS-penetrant FPR2 agonist with an EC50 of 0.13 μM, 1.1 μM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity[1].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FPR2 agonist 2 | 98.51% | FPR2 agonist 2 is a potent and CNS-penetrant FPR2 agonist with an EC50 of 0.13 μM, 1.1 μM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Autophagy-IN-3 | Autophagy-IN-3 (Compound 6k) is an autophagy inhibitor. Autophagy-IN-3 promotes metabolic stress in the tumor microenvironment and enhances the effects of cytostatics in combined treatments. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Benzoyl-L-tyrosine p-nitroanilide | 95.75% | N-Benzoyl-L-tyrosine p-nitroanilide is a chymotrypsin substrate. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anticancer agent 151 | Anticancer agent 151 (compound 6C) is an anticancer agent. Anticancer agent 151 exhibits excellent in vitro cytotoxic activity against MCF-7 cells with an IC50 value of 6.3 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FPR2 agonist 3 | 99.39% | FPR2 agonist 3 (compound CMC23) can limit the lactate dehydrogenase release in LPS (HY-D1056) -stimulated cultures and decrease the levels of pro-inflammatory IL-1β and IL-6. FPR2 agonist 3 decrease the level of phosphor-STAT3 via the STAT3/SOCS3 signaling pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
P2X7 receptor antagonist-6 | P2X7 receptor antagonist-6 (Compound 2g) is a negative allosteric P2X7 receptor antagonist with an IC50 of 1.31 μM for hP2X7. P2X7 receptor antagonist-6 can be used for cancer, neurodegenerative, inflammatory, and infectious diseases research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IDO1-IN-28 | 99.89% | IDO1-IN-28 (Compound MQ-1) is a Apo-IDO1 inhibitor with an IC50 of 1.29 μM. IDO1-IN-28 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-28 can be used for cancers research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IDO1-IN-29 | IDO1-IN-29 (Compound MQ-1n) is a Apo-IDO1 inhibitor with an IC50 of 0.29 μM. IDO1-IN-29 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-29 can be used for cancers research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MR-39 | MR-39 is a FPR2 agonist (EC50 = 3.9 μM). MR-39 activates FPR2 to promote neuroinflammation resolution (downregulates IL-1β and TNF-α, modulates NF-κB), upregulates synaptic proteins (synaptic proteins) and improves dendritic spine morphology. MR-39 inhibits MAPK/ERK and AKT phosphorylation in glioblastoma, induces S-phase arrest, and suppresses migration, angiogenesis, and hypoxic adaptation. MR-39 reduces Aβ plaque burden via inhibiting MyD88/NF-κB and NLRP3 inflammasome. MR-39 can be used for research on autism spectrum disorder, Alzheimer's disease, and glioblastoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bentiromide (Standard) | ≥98% | Bentiromide (Standard) is the analytical standard of Bentiromide. This product is intended for research and analytical applications. Bentiromide is a peptide that is broken down in the pancreas by chymotrypsin. The bentiromide test is an excellent means of confirming the diagnosis of pancreatic exocrine insufficiency by outpatient test of chymotrypsin function. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ID110460002 | ID110460002 possesses both full agonist activity at the μ-opioid receptor (OPRM) and agonist activity at the δ-opioid receptor (OPRD). ID110460002 acts as a potent agonist for the G protein pathways of both receptors, but exhibits only very weak partial agonist activity towards the β-arrestin-2 pathway. The agonistic potency of ID110460002 at OPRM has extremely high intrinsic activity and is unaffected by reduced receptor expression levels, while its potency at OPRD depends on receptor expression levels. ID110460002 displays tissue- or organ-dependent properties, and serves as a critical compound for investigating pain mechanisms and analgesia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
